APLS

43.90

10.06% -4.91

Dopo l'orario di chiusura: 44.00 0.10 +0.23%

Apellis Pharmaceuticals Inc (APLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché APLS Giù? Forum Previsione

Precedente Chiudi:

$48.81

Aprire:

$45.1

Volume 24 ore:

4.52M

Capitalizzazione di mercato:

$5.32B

Reddito:

$396.59M

Utile/perdita netta:

$-528.63M

Rapporto P/E:

-8.3619

EPS:

-5.25

Flusso di cassa netto:

$-595.51M

1 W Prestazione:

-0.66%

1M Prestazione:

-21.48%

6M Prestazione:

-7.19%

1 anno Prestazione:

-52.89%

Intervallo 1D:

$41.75

$47.60

Portata 52W:

$19.83

$94.75

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Nome

Apellis Pharmaceuticals Inc

Settore

Healthcare (1216)

Industria

Biotechnology (698)

Telefono

502-241-4114

Indirizzo

6400 Westwind Way, Suite A, Crestwood, KY

Dipendente

Cinguettio

@ApellisPharma

Prossima data di guadagno

2024-06-05

Ultimi documenti SEC

APLS's Discussions on Twitter

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-05	Aggiornamento	Jefferies	Hold → Buy
2023-12-14	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-11-09	Iniziato	Goldman	Buy
2023-11-02	Iniziato	Mizuho	Neutral
2023-10-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-09-15	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-08-29	Reiterato	Citigroup	Buy
2023-08-03	Downgrade	JP Morgan	Overweight → Neutral
2023-08-01	Downgrade	BofA Securities	Buy → Neutral
2023-01-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2022-11-10	Downgrade	Jefferies	Buy → Hold
2022-07-19	Iniziato	H.C. Wainwright	Buy
2022-06-17	Ripresa	Stifel	Buy
2022-04-14	Downgrade	ROTH Capital	Neutral → Sell
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-11-29	Downgrade	ROTH Capital	Buy → Neutral
2021-09-10	Reiterato	BMO Capital Markets	Outperform
2021-09-10	Reiterato	Credit Suisse	Neutral
2021-09-10	Reiterato	Needham	Buy
2021-09-10	Reiterato	Oppenheimer	Outperform
2021-09-10	Downgrade	Wedbush	Outperform → Neutral
2021-08-19	Iniziato	Jefferies	Buy
2021-08-19	Aggiornamento	Wedbush	Neutral → Outperform
2021-05-21	Iniziato	UBS	Buy
2021-04-16	Iniziato	Goldman	Buy
2020-11-19	Iniziato	Needham	Buy
2020-09-01	Iniziato	Stifel	Buy
2020-07-20	Iniziato	ROTH Capital	Buy
2020-06-17	Iniziato	BTIG Research	Neutral
2020-04-01	Iniziato	Raymond James	Strong Buy
2020-03-31	Iniziato	BMO Capital Markets	Outperform
2020-03-11	Aggiornamento	Wedbush	Underperform → Neutral
2020-01-07	Iniziato	SVB Leerink	Mkt Perform
2019-12-19	Iniziato	BofA/Merrill	Buy
2019-11-22	Iniziato	Wedbush	Underperform
2019-11-05	Iniziato	Credit Suisse	Neutral
2019-08-01	Reiterato	Cantor Fitzgerald	Overweight
2019-07-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-03-29	Iniziato	Robert W. Baird	Outperform
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-07-30	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-05-24	Iniziato	Cantor Fitzgerald	Overweight
2018-04-12	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

Zacks Investment Research

Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

GlobeNewswire Inc.

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari

Apellis Pharmaceuticals Inc (APLS) Reddito 2024

APLS ha riportato un ricavo (TTM) di $396.59 milioni per il trimestre terminato il 2023-12-31, un +425.83% salita anno su anno.

Apellis Pharmaceuticals Inc (APLS) Reddito netto 2024

APLS l'utile netto (TTM) è stato di -$528.63 milioni per il trimestre terminato il 2023-12-31, un +18.94% aumento anno su anno.

Apellis Pharmaceuticals Inc (APLS) Flusso di cassa 2024

APLS ha registrato un flusso di cassa disponibile (TTM) di -$595.51 milioni per il trimestre conclusosi con 2023-12-31, un -15.57% diminuire anno su anno.

Apellis Pharmaceuticals Inc (APLS) Utile per azione 2024

L'utile per azione (TTM) di APLS è stato pari a -$4.48 per il trimestre terminato il 2023-12-31, un +26.92% crescita anno su anno.

Apellis Pharmaceuticals Inc Azioni (APLS) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Dunlop A. Sinclair	Director	Apr 12 '24	Option Exercise	13.19	1,500	19,785	133,518
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Option Exercise	3.76	69,107	259,842	1,185,090
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Sale	54.17	69,107	3,743,605	1,115,983
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Option Exercise	10.03	4,000	40,120	97,338
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Sale	58.66	4,000	234,640	93,338
Dunlop A. Sinclair	Director	Mar 19 '24	Sale	57.18	18,681	1,068,161	173,998
DeLong Mark Jeffrey	Chief Business & Strat Officer	Mar 18 '24	Sale	56.90	9,913	564,050	54,693
Chopas James George	VP/Chief Accounting Officer	Mar 15 '24	Sale	56.46	184	10,389	38,883
Nicholson Nur	Chief Technical Officer	Mar 13 '24	Sale	57.56	11,220	645,838	56,287
Deschatelets Pascal	Chief Scientific Officer	Mar 08 '24	Option Exercise	3.67	69,107	253,623	1,185,090